Interleukin-2 in neuroblastoma: Clinical perspectives based on biological studies

Cancer Biotherapy and Radiopharmaceuticals

Volumn 11, Issue 5, 1996, Pages 303-308

  Rueda, Felix ^a,c   Martí, Francesc ^a   Pardo, Núria ^b   Badell, Isabel ^b   Peiró, Matilde ^a   Bertran, Esther ^a   Villén, Esther ^a   García, Juan ^a   Cubells, Josep ^b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL DURAN I REYNALS   (Spain)

Author keywords

autologous bone marrow transplantation; IL2 treatment; lymphokine activated killer; Natural killer; neuroblastoma

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CELL SURFACE MARKER; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2;

ARTICLE; BONE MARROW TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CELL ISOLATION; DATA ANALYSIS; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; LYMPHOKINE ACTIVATED KILLER CELL; NATURAL KILLER CELL; NEUROBLASTOMA; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RAJI CELL; REMISSION; TREATMENT PLANNING;

BONE MARROW TRANSPLANTATION; HUMANS; INTERLEUKIN-2; KILLER CELLS, NATURAL; NEUROBLASTOMA; TRANSPLANTATION, AUTOLOGOUS;

EID: 0030459612     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Shuster JJ, Cantor AB, McWilliams N, Graham-Pole J, Castleberry RP, Marcus R, Pick T, Smith EI, Hayes FA. The prognostic significance of autologous bone marrow transplantation in advanced neuroblastoma. J Clin Oncol 1991;9:1045.
2. Ladenstein R, Lasset C, Hartman O, Frappaz D, Garaventa A, Klingebiel T, Zucker JM, Coze C, Burdach S, Gadner H, Paolucci P, Pearson A, Pinkerton R, Chauvin F, Philip T. Impact of megatherapy on survival after relapse from stage 4 neuroblastoma in patients over one year of age at diagnosis: A report from the European group for bone marrow transplantation. J Clin Oncol 1993;11:2330.
3. Rill DR, Santana VM, Roberts WM, Nilson T, Bowman LC, Krance RA, Heslop HE, Moen RC, Ihle JN, Brenner MK. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994;84:380.
4. Weite K, Ciobanu N, Moore MAS, Gulati S, O'Reilly RJ, Mertelsmann R Defective interleukin-2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin-2. Blood 1994;64:380.
5. Niederwieser D, Gastl G, Rumpold H, Marth CH, Kraft D, Huber CH. Rapid reappearance of large granular lymphocytes (LGL) with concomitant reconstitution of natural killer (NK) activity after human bone marrow transplantation (BMT). Br J Haematol 1987;65:301.
6. + natural killer cells after bone marrow transplantation. Blood 1992;79 3239.
7. Biaise DO, Stoppa AM, Viens P, Pourreau C, Lopez M, Attal M, Jasmin C. Monges G, Mawas C, Mannoni P, Palmer P, Franks C, Philip T, Maraninchi D. Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1990;79:1092.
8. Arancia G and Donelli G. Surface features of human lymphocytes. EOS J Immunol Immunopharmacol 1988;8:96.
9. Lanier LL, Le AM, Civin CI, Loken MR and Philips JH. The relationship of CD16 (leu-11) and leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytolytic T lymphocytes. J Immunol 1986;136:4480.
10. Nagler A, Lanier LL, Cwirla S, and Phillips JH. Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 1989;143:3183.
11. Castel VS, Badal MI, Bezanilla JLR, Herrero AD, Lombart AB, Ruiz JJ, Sanchez de Toledo J. Neuroblastoma. Resultados del protocole N-I-87. An Esp Pediatr 1993;38(5):471.
12. Martí F, Miralles A, Peiró M, Amill B, Dalmases C, Piñol G, Rueda F, and García J. Differential effect of cryopreservation on natural killer and lymphokine activated killer activities. Transfusion 1993;33:651.
13. Pardo N, Martí F, Peiró M, Bertran E, Fraga G, Amill B, Illa J, Rueda F, and Cubells J Immunotherapy with high doses of interleukin-2 after autologous bone marrow transplantation in childhood neuroblastoma patients. I. Following of tolerance and clinical response. Anales de Pediatria Espanola 1995:(In press).
14. Richards SJ and Scott CS. Immunophenotypic dissection of normal peripheral blood NK associated NKa) subpopulations by flow cytometry: Morphological features and relationships between membrane NKa (CD11b, CD16, CD56 and CD57) and T-cell (CD2, CD3, TCR, CD5, CD7, CD8 and CD38) associated determinant expression. Leuk Lymphoma 1990,2:111.
15. López-Härminen E, Körfer A, Hadam M, Schneekloth C, Dallmann I, Menzel T, Kirchner H, Poliwoda H, and Atzpodien J. Biological monitoring of low-dose interleukin 2 in human: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes. Cancer Res 1991;50:6312.
16. Fuchshuber PR and Lotzová E. Differential oncolytic effect of NK-enriched subsets in long-term interleukin-2 cultures. Lymphokine Cytokine Res 1992;11:271.
17. Prigione I, Facchetti P, Lanino E, Garaventa A, Pistoia V. Clonal analysis of peripheral blood lymphocytes from three patients with advanced neuroblastoma receiving recombinant interleukin 2 and interferon alpha. Cancer Immunol Immunother 1993;37:40.
18. - large granular lymphocytes. Eur J Immunol 1993;23:697-701.
19. Rossi AR, Pericle F, Rashleigh S, Janiec J, and Djeu JY. Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12. Blood 1994;83:1323.
20. H. Tumour Biology 1993;14(6) 354.